{"title":"鞘内右美托咪定用于剖宫产:范围回顾","authors":"P. Vozzo , S. Zilber , R. Landau","doi":"10.1016/j.ijoa.2025.104738","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Off-label use of intrathecal dexmedetomidine (ITDex) is suggested in recent guidelines for pain management during cesarean delivery. The primary objective of this scoping review was to identify all publications reporting on ITDex for cesarean delivery, and secondarily to evaluate the evidence and characterize reported outcomes associated with its use.</div></div><div><h3>Methods</h3><div>Following PRISMA-Scr guidelines, we searched PubMed and Embase in October 2024 for articles reporting on ITDex for cesarean delivery and conducted a scoping review on randomized controlled trials (RCTs) and observational trials. A chart data with seven questions characterizing the studies and 13 evaluating clinical outcomes was developed.</div></div><div><h3>Results</h3><div>Our search identified 48 publications in English between 2015 and October 2024: 43 RCTs, three observational trials, two case reports/series, resulting in 2,002 patients receiving ITDex (dose ranging 1–35 <span><math><mrow><mi>μ</mi><mi>g</mi><mo>)</mo></mrow></math></span>. Primary outome was stated in 31 (65 %) studies. There were seven dose-ranging studies, one study with fentanyl co-administration, none with morphine co-administration, three compared ITDex vs. clonidine (clonidine dose ranging 15–75 <span><math><mrow><mi>μ</mi><mi>g</mi><mo>)</mo></mrow></math></span>; 35 reported on shivering, 36 on block characteristics (onset and block duration), 38 evaluated postoperative analgesia, nine reported on pain during cesarean delivery.</div></div><div><h3>Discussion</h3><div>Dexmedetomidine may be a valuable intrathecal adjuvant for cesarean delivery but the quality of study design and data reporting in the 48 publications was extremely poor. Though we identified 43 RCTs with at least one arm receiving ITDex, no study incorporated current multimodal opioid-sparing analgesia regimens (administration of intrathecal fentanyl and morphine with or without dexmedetomidine), therefore significant knowledge gaps remain.</div></div>","PeriodicalId":14250,"journal":{"name":"International journal of obstetric anesthesia","volume":"64 ","pages":"Article 104738"},"PeriodicalIF":2.3000,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Intrathecal dexmedetomidine for cesarean delivery: a scoping review\",\"authors\":\"P. Vozzo , S. Zilber , R. Landau\",\"doi\":\"10.1016/j.ijoa.2025.104738\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Off-label use of intrathecal dexmedetomidine (ITDex) is suggested in recent guidelines for pain management during cesarean delivery. The primary objective of this scoping review was to identify all publications reporting on ITDex for cesarean delivery, and secondarily to evaluate the evidence and characterize reported outcomes associated with its use.</div></div><div><h3>Methods</h3><div>Following PRISMA-Scr guidelines, we searched PubMed and Embase in October 2024 for articles reporting on ITDex for cesarean delivery and conducted a scoping review on randomized controlled trials (RCTs) and observational trials. A chart data with seven questions characterizing the studies and 13 evaluating clinical outcomes was developed.</div></div><div><h3>Results</h3><div>Our search identified 48 publications in English between 2015 and October 2024: 43 RCTs, three observational trials, two case reports/series, resulting in 2,002 patients receiving ITDex (dose ranging 1–35 <span><math><mrow><mi>μ</mi><mi>g</mi><mo>)</mo></mrow></math></span>. Primary outome was stated in 31 (65 %) studies. There were seven dose-ranging studies, one study with fentanyl co-administration, none with morphine co-administration, three compared ITDex vs. clonidine (clonidine dose ranging 15–75 <span><math><mrow><mi>μ</mi><mi>g</mi><mo>)</mo></mrow></math></span>; 35 reported on shivering, 36 on block characteristics (onset and block duration), 38 evaluated postoperative analgesia, nine reported on pain during cesarean delivery.</div></div><div><h3>Discussion</h3><div>Dexmedetomidine may be a valuable intrathecal adjuvant for cesarean delivery but the quality of study design and data reporting in the 48 publications was extremely poor. Though we identified 43 RCTs with at least one arm receiving ITDex, no study incorporated current multimodal opioid-sparing analgesia regimens (administration of intrathecal fentanyl and morphine with or without dexmedetomidine), therefore significant knowledge gaps remain.</div></div>\",\"PeriodicalId\":14250,\"journal\":{\"name\":\"International journal of obstetric anesthesia\",\"volume\":\"64 \",\"pages\":\"Article 104738\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-07-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of obstetric anesthesia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0959289X25003309\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ANESTHESIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of obstetric anesthesia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959289X25003309","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
Intrathecal dexmedetomidine for cesarean delivery: a scoping review
Background
Off-label use of intrathecal dexmedetomidine (ITDex) is suggested in recent guidelines for pain management during cesarean delivery. The primary objective of this scoping review was to identify all publications reporting on ITDex for cesarean delivery, and secondarily to evaluate the evidence and characterize reported outcomes associated with its use.
Methods
Following PRISMA-Scr guidelines, we searched PubMed and Embase in October 2024 for articles reporting on ITDex for cesarean delivery and conducted a scoping review on randomized controlled trials (RCTs) and observational trials. A chart data with seven questions characterizing the studies and 13 evaluating clinical outcomes was developed.
Results
Our search identified 48 publications in English between 2015 and October 2024: 43 RCTs, three observational trials, two case reports/series, resulting in 2,002 patients receiving ITDex (dose ranging 1–35 . Primary outome was stated in 31 (65 %) studies. There were seven dose-ranging studies, one study with fentanyl co-administration, none with morphine co-administration, three compared ITDex vs. clonidine (clonidine dose ranging 15–75 ; 35 reported on shivering, 36 on block characteristics (onset and block duration), 38 evaluated postoperative analgesia, nine reported on pain during cesarean delivery.
Discussion
Dexmedetomidine may be a valuable intrathecal adjuvant for cesarean delivery but the quality of study design and data reporting in the 48 publications was extremely poor. Though we identified 43 RCTs with at least one arm receiving ITDex, no study incorporated current multimodal opioid-sparing analgesia regimens (administration of intrathecal fentanyl and morphine with or without dexmedetomidine), therefore significant knowledge gaps remain.
期刊介绍:
The International Journal of Obstetric Anesthesia is the only journal publishing original articles devoted exclusively to obstetric anesthesia and bringing together all three of its principal components; anesthesia care for operative delivery and the perioperative period, pain relief in labour and care of the critically ill obstetric patient.
• Original research (both clinical and laboratory), short reports and case reports will be considered.
• The journal also publishes invited review articles and debates on topical and controversial subjects in the area of obstetric anesthesia.
• Articles on related topics such as perinatal physiology and pharmacology and all subjects of importance to obstetric anaesthetists/anesthesiologists are also welcome.
The journal is peer-reviewed by international experts. Scholarship is stressed to include the focus on discovery, application of knowledge across fields, and informing the medical community. Through the peer-review process, we hope to attest to the quality of scholarships and guide the Journal to extend and transform knowledge in this important and expanding area.